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Introduction:Neutrophils can be induced to release DNA combinedwith histones. The resulting neutrophil extra-
cellular trap (NET) provides a scaffold for growing hemostatic plug. Therefore, the NET formation may be inevi-
table in clinical conditions that are characterized by formation of vascular thrombi. Thus far, there have been
no reports on the clinical signiﬁcance of NET in disseminated intravascular coagulation (DIC). Therefore, we
investigated circulating levels of NET in DIC and analyzed their potential values to assess coagulation severity
and predict clinical outcome.
Methods: The plasma levels of DNA-histone complexes and double-stranded DNA (dsDNA), considered to be
in vivo markers of NET, were measured in 199 patients suspected of having DIC and 20 healthy controls.
Result: The circulating levels of DNA-histone complexes and dsDNA were signiﬁcantly elevated in overt-DIC.
The increased levels of these two markers correlated with the severity of coagulopathy including DIC score
and D-dimer. Multivariable Cox regression analysis, adjusted for the conventional DIC markers, revealed that
elevated DNA-histone complexes and dsDNA are poor independent prognostic markers.
Conclusion: The circulating levels of NET release reﬂect the coagulation activation and adverse clinical outcomes
in patients with DIC, thereby providing potential clinical relevance for mortality prediction in DIC.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In recent studies, neutrophils have been reported to play an essential
role in thrombosis [1]. When pathogens such as bacteria invade the cir-
culation, neutrophils defend against the pathogens, through the release
of neutrophil extracellular trap (NET). The NET not only binds to the
pathogens, it also entraps the platelets and red blood cells that are the
main components of vascular thrombi. Meshwork of DNA strands
around histones from the main skeleton of NET [1]. Histones can acti-
vate platelets, induce endothelial cell damage, and inhibit anticoagulant
protein C activation [2,3]. Therefore, it is likely that they promote
thrombin formation.isseminatedintravascularcoag-
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. This is an open access article underNET is triggered not only by infectious pathogens, but also by reac-
tive oxygen species, antibodies, and activated platelets [4]. As a result,
an increase of NET formation has been reported in various clinical
conditions including sepsis, trauma, autoimmune diseases, deep vein
thrombosis, atherosclerosis, and thrombotic microangiopathy [5–10].
Disseminated intravascular coagulation (DIC) is characterized by
systemic activation of coagulation and anticoagulation pathways lead-
ing to ﬂorid ﬁbrin deposition and formation of microthrombi [11,12].
The underlying conditions of DIC such as sepsis and trauma are
known to promote NET formation [2,10]. Since NET contributes to
thrombus formation, we presumed that DIC process is closely related
with increased NET formation and the resulting NET may in turn pro-
mote hypercoagulability. Hence, in the present study we investigated
circulating levels of NET in patients suspected of having DIC and ana-




A total of 199 patients who were clinically suspected of having DIC
and who underwent DIC screening battery tests were enrolled in thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
The characteristics of the study population.









Age, yrs, 57.1 ± 18.4 53.0 ± 17.8 55.2 ± 18.4 59.8 ± 17.6
Male/Female (%) 88 (60.3)/ 58 (39.7) 34 (64.2)/19 (35.8) 104 (62.7)/62 (37.3) 18 (54.5)/15 (45.5)
Clinical diagnosis, n (%)
Sepsis/severe infection 23 (15.8) 8 (15.1) 23 (13.9) 8 (24.2)
Solid malignancies 63 (43.2) 20 (37.7) 72 (43.4) 11 (33.3)
Hematologic malignancies 25 (17.1) 13 (24.5) 25 (15.1) 13 (39.4)
Organ destruction 6 (4.1) 2 (3.8) 8 (4.8) 0 (0.0)
Trauma 4 (2.7) 0 (0.0) 4 (2.4) 0 (0.0)
Severe hepatic failure 4 (2.7) 8 (15.1) 11 (6.6) 1 (3.0)
Severe toxic or immunologic reaction 9 (6.2) 0 (0.0) 9 (5.4) 0 (0.0)
Vascular abnormalities 6 (4.1) 2 (3.8) 8 (4.8) 0 (0.0)
Obstetrical calamities 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other† 6 (4.1) 0 (0.0) 6 (3.6) 0 (0.0)
Neutrophil (x109/L) 7.20 ± 8.76 6.22 ± 6.42 6.95 ± 8.49 6.90 ± 6.57
Platelets (x109/L) 160 ± 116⁎⁎ 60.3 ± 67.9 142 ± 115⁎ 88.4 ± 97.0
PT (sec) 14.1 ± 9.37⁎ 18.4 ± 5.08 15.1 ± 9.18 16.0 ± 5.25
aPTT (sec) 33.8 ± 8.72⁎⁎ 39.1 ± 10.9 34.7 ± 9.40 37.8 ± 10.4
D-dimer (μg/mL) 5.11 ± 11.2⁎ 10.7 ± 16.4 6.16 ± 13.0 8.87 ± 13.1
Fibrinogen (mg/dL) 360 ± 119⁎⁎ 269 ± 164 343 ± 135 302 ± 152
Protein C (%) 74.9 ± 30.7⁎⁎ 43.0 ± 28.9 69.2 ± 33.2⁎ 52.3 ± 30.5
Antithrombin (%) 75.7 ± 21.9⁎⁎ 52.6 ± 23.5 72.1 ± 24.2⁎ 56.7 ± 22.2
DNA-histone complex (AU) 146 ± 246⁎ 232 ± 286 131 ± 198⁎⁎ 356 ± 412
dsDNA (ng/ml) 2.99 ± 2.51⁎⁎ 4.62 ± 4.13 2.94 ± 2.29⁎⁎ 5.89 ± 4.98
Values are presented as themean± standard deviation. †Other clinical diagnoses included organ destruction (n= 1), diabetes mellitus (n= 3), and chronic kidney disease (n= 2).
a Total population was classiﬁed into two groups in terms of overt-DIC criteria. b Total population was divided into survivor and non-survivor according to 150-day mortality.
⁎ P b 0.05, ⁎⁎ P b 0.001.
Abbreviations: DIC, disseminated intravascular coagulation; PT, prothrombin time; aPTT, activated partial thromboplastin time, dsDNA; double stranded DNA.
1065J.-E. Kim et al. / Thrombosis Research 135 (2015) 1064–1069study. Written consent from patient was exempted, since all data were
acquired anonymously and retrospectively from laboratory information
system without any additional blood sampling. Exclusion criteria were
thrombotic or bleeding disorders, use of warfarin or heparin medica-
tions within 3 days of blood collection, or pediatric patients. In addition,
20 healthy adults were enrolled under written informed consent in
order to determine the reference range of circulating NET levels. The In-
stitutional ReviewBoard of Seoul National University Hospital approved
this study.
The patients’ characteristics are described in Table 1. Patients
were diagnosed as having overt-DIC, whichwas deﬁned as a cumula-
tive score of ≥5 by the International Society of Thrombosis and
Haemostasis (ISTH) Sub-Committee scoring system [12]. We arbi-
trarily classiﬁed the patients who did not meet the criteria of overt-
DIC as no overt-DIC.Fig. 1. Trend of circulating levels of DNA-histone complex (A) and dsDNA (B) bBlood Samples and Assays
Peripheral blood was collected in sodium citrate tubes (Becton
Dickinson, San Jose, CA, USA). The whole blood samples were centri-
fuged for 15minutes at 1550 x gwithin 2 hours after samplewithdraw-
al. The prothrombin time (PT), activated partial thromboplastin time
(aPTT), and ﬁbrinogen were assayed on an ACL 3000 automated
coagulation analyzer (Instrumentation Laboratory, Milan, Italy)
using HemosIL RecombiPlasTin and SynthASil reagents (Instrumentation
Laboratory). D-dimer was tested by an immunoturbidimetric assay
(Instrumentation Laboratory). Antithrombin and protein C activity were
measured by a chromogenic assay (HemosIL Antithrombin and Protein
C; Instrumentation Laboratory).
The circulating levels of NET in plasma were quantiﬁed using two
commercial kits; The DNA-histone complex was quantiﬁed using anased on disseminated intravascular coagulation (DIC) score in all patients.
Fig. 3. Receiver operating characteristic (ROC) curves and the area under the ROC curves
(AUC) for DNA-histone complexes, dsDNA, platelets and D-dimer for mortality
prediction in disseminated intravascular coagulation. Diamond points (◆) represent the
optimal cutoff point corresponding to Youden index.
Fig. 2. Association of circulating levels of DNA-histone complex (A) and dsDNA (B) with the D-dimer levels in all patients.
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the double-stranded DNA (dsDNA) was measured using Quant-iT
PicoGreen dsDNA reagent (Molecular Probes, Eugene, OR, USA) and a
microplate ﬂuorometer (Fluoroskan Ascent, Thermo Fisher Scientiﬁc
Inc., MA, USA) according to the manufacturer’s guidelines.
Statistical Analysis
All statistical analyses were performed using SPSS 17.0 forWindows
(SPSS Inc., Chicago, IL, USA). Data comparisons were carried out using
the t-test or chi-square test. Receiver operating characteristic (ROC)
curve analysis was carried out for mortality prediction of each parame-
ter. ROC curve analysis using MedCalc (Mariakerke, Belgium) was used
to determine the optimal cutoff value. Kaplan–Meier survival analysis
was used to analyze the cumulative survival curves. Univariable
and multivariable Cox regression analyses were carried out to identify
signiﬁcant prognostic markers. Two-sided P-values of b0.05 were
considered to be statistically signiﬁcant.
Results
Circulating Levels of DNA-histone Complex and dsDNA in Relation to
Coagulation Severity
According to the DIC scoring system criteria, 53 out of the total 199
patients were found to be with overt-DIC (Table 1). There were no dif-
ferences seen with respect to age and sex, between overt-DIC group
and no overt-DIC group. The well-known DIC parameters including
platelets, PT, aPTT, D-dimer, and ﬁbrinogen showed signiﬁcant changes
in overt-DIC. The decrease in protein C and antithrombin levels was
found to be more in overt-DIC than in no overt-DIC. Overt-DIC patients
showed signiﬁcantly high levels of DNA-histone complexes and dsDNA
as compared to the levels in no overt-DIC. The reference range of DNA-
histone complex and dsDNA established by testing 20 normal healthy
controls (mean age 46; 12 males and 8 females) were 0-56 AU and
1.71-1.99 ng/mL, respectively. Even no overt-DIC patients were found
to have markedly higher levels of DNA-histone complexes (146 ±
246 AU) and dsDNA (2.99±2.51 ng/mL) than those in healthy controls.
Statistically, the DNA-histone complex levels strongly correlated with
dsDNA levels (r = 0.544, P b 0.001).
The circulating levels of DNA-histone complexes and dsDNA were
found to increase gradually in relation to theDIC score (Fig. 1).When di-
vided into 3 tertile groups according to the D-dimer levels, the mean
values of DNA-histone complex and dsDNA correlated with D-dimer
levels (Fig. 2).Prognostic Values of Circulating DNA-histone Complex and dsDNA Levels
Non-survivors were arbitrarily deﬁned as patients who were dead
within 28-hospital days. Out of the total 199 patients, 33 were catego-
rized as non-survivors (Table 1). There were no signiﬁcant differences
in age and sex between survivors and non-survivors. Platelet counts
were decreased in non-survivors whereas PT, D-dimer, and ﬁbrinogen
levels were not signiﬁcantly different between survivors and non-
survivors. Plasma levels of protein C and antithrombin were signiﬁcant-
ly decreased in non-survivors as compared to that in survivors. The
increase in the circulating levels of DNA-histone complexes and
dsDNA was signiﬁcantly higher in non-survivors than in survivors.
The prognostic values of DNA-histone complexes and dsDNA were
evaluated using ROC curves. The AUC of DNA-histone complexes and
dsDNA were slightly higher than that of platelet and D-dimer (Fig. 3).
For Kaplan-Meier analysis, the total populationwas divided into two
groups according to the cutoff values that provided the best prognostic
power in the ROC analysis. Among all patients, the group with high
Table 2
Univariable and multivariable Cox regression analysis for mortality prediction in all patients.
Univariable Multivariable
Variables HR 95% CI P value HR 95% CI P value
Platelet (≤55 x 109 vs. N55 x 109/L) 3.15 1.57–6.32 0.001 2.24 1.10–4.59 0.027
PT (N13.2 vs. ≤13.2 sec) 2.96 1.40–6.22 0.004 1.96 0.84–4.58 0.119
D-dimer (N3.69 vs. ≤3.69 mg/mL) 2.41 1.20–4.85 0.014 1.31 0.60–2.85 0.493
Fibrinogen (≤274 vs. N274 mg/dL) 0.47 0.24–0.93 0.031 0.75 0.36–1.56 0.439
Antithrombin (≤62 vs. N62 μg/L) 2.53 1.18–5.44 0.018 1.08 0.45–2.62 0.862
Protein C (≤72 vs. N72 pg/mL) 3.99 1.54–10.35 0.004 2.51 0.78–8.14 0.124
DNA-histone (N357 vs. ≤357 AU) 5.66 2.78–11.52 0.000 3.89 1.65–9.15 0.002
dsDNA (N3.23 vs. ≤3.23 ng/ml) 4.93 2.45–9.91 0.000 2.41 1.04–5.55 0.039
The cut-off values were determined as the values which produced the best prognostic value.
Abbreviation: HR, hazard ratio; CI, conﬁdence interval; PT, prothrombin time; dsDNA, double stranded DNA.
Fig. 4. Kaplan-Meier survival analysis stratiﬁed for DNA-histones complex and dsDNA levels in all patients (A, B), cancer patients (C, D), and non-cancer patients (E, F). Values with the
highest prognostic power to predict the 28-day mortality were set as the cut-off values.
1067J.-E. Kim et al. / Thrombosis Research 135 (2015) 1064–1069
1068 J.-E. Kim et al. / Thrombosis Research 135 (2015) 1064–1069DNA-histone (N357 AU) or dsDNA (N3.23 ng/mL) exhibited poor sur-
vival rates compared to the group with low DNA-histone or dsDNA
(Fig. 4A, B). Similarly, among cancer patients, the groupwith high levels
of DNA-histone (N357 AU) or dsDNA (N5.13 ng/mL) showed poorer
survival than the group with low levels of DNA-histone or dsDNA
(Fig. 4C, D). Likewise, in non-cancer patients, the groupwith high levels
of DNA-histone or dsDNA showed poor prognosis, although the statisti-
cal signiﬁcance of non-cancer patients was slightly less than that of
cancer patients (Fig. 4E, F).
Univariable Cox regression analysis showed signiﬁcant hazard ratios
for platelets, PT, D-dimer, ﬁbrinogen, antithrombin, and protein C
(Table 2). Notably, the hazard ratios of DNA-histone (5.66) and dsDNA
(4.93) were higher than that of D-dimer (2.41) (Table 2). In multivari-
able Cox regression analysis, the conventional DIC markers except
platelet count lost their prognostic signiﬁcance ofmortality. Interesting-
ly, DNA-histone and dsDNA were revealed as independent prognostic
factors.
Discussion
Neutrophils can be induced by pathogens or other stimuli to release
DNA combinedwith histones and cytoplasmic components such as neu-
trophil elastase, myeloperoxidase, and cathepsin G [13]. The resulting
NET provides a scaffold to grow a hemostatic plug. Therefore, the NET
formationmay be inevitable in clinical conditions that are characterized
by formation of vascular thrombi. Even though NET is known to be an
important scaffold for vascular thrombi, there has been no data on the
clinical signiﬁcance of NET in DIC. Our study demonstrated that the
levels of circulating DNA-histone complexes and dsDNA gradually in-
creased in accordance with DIC severity. In addition, the elevated levels
of circulating DNA-histone complexes and dsDNA showed independent
prognostic signiﬁcance.
Our data provide an interesting insight for the association of
NET with coagulation severity. There have been several reports
that explain how the NET contributes to coagulation activation [1,3,7].
Nucleic acids can bind coagulation factor XII and XI, thereby
activating the intrinsic pathway [14]. The histones can increase
thrombin formation by impairment of thrombomodulin-dependent
protein C activation [15]. Histones can also activate platelets and en-
dothelial cells [2,3]. In animal models, histone infusion has been
shown to increase platelet-rich microthrombi [16]. Considering
these effects of NET on coagulation activation in the previous reports,
it is plausible that the increased levels of DNA-histone complex and
dsDNA play a role in the ampliﬁcation of coagulation activation in
DIC processes.
One of the intriguing ﬁndings of our study was that the increased
levels of DNA-histone complexes and dsDNA showed powerful
prognostic values that were independent of the already known
prognostic DIC markers. This suggests that the continuous formation
of NET in patients with DIC could not only amplify the coagulation
activation and but also affect other detrimental damage to the host
[17]. As activated protein C is known to cleave histones [2], the
decreased level of activated protein C in patients with advanced
DIC may aggravate histone removal and result in high mortality. In
other words, NET formation is thought to play a role in a vicious
cycle of hypercoagulability.
Several reports have indicated the presence of extracellular nuclear
proteins that are released from dying cells during sepsis [17,18]. Elevat-
ed levels of circulating nucleosome, high mobility group box-1, and
plasma DNA were observed in critically ill patients [17,19,20]. Further-
more, high nucleosome levels have also been reported in advanced
cancer patients [21]. This increase may originate from enhanced cell
death or from impaired degradation of nucleosomes in serumby deoxy-
ribonuclease (DNase) [9,22]. In view of various underlying clinical
conditions in our study population, it is not easy to clearly identify the
kind of factor(s) that increased the NET formation. In the presentstudy, the main underlying conditions of DIC were sepsis, severe infec-
tions, and malignancies; therefore, the main contributor of NET
formation is likely to be cell death induced by various stimuli.
The neutrophil elastase has been found to digest cross-linked ﬁbrin
in DIC, ﬁnally increasing plasma level of cross-linked ﬁbrin degradation
product by elastase (e-XDP) [23]. Although our study didn’t measure
the e-XDP level, it is likely to correlate the NET markers with e-XDP,
because NET formation induces a large amount of neutrophil elastase
which increases the e-XDP level.
Circulating levels of DNA-histone complexes and dsDNA may be
dependent on neutrophil counts partly, because they are released
from neutrophil. However in our study the DNA-histone complexes
and dsDNA levels were not different among subtype of hematologic
malignancies (data not shown). Future study may be required to in-
vestigate the effect of peripheral neutrophil count on DNA-histone
complexes and dsDNA levels in resting status.
Cancer is considered to be a signiﬁcant contributor to the formation
of circulating NET [21]. Therefore, we divided the test population
into cancer and non-cancer groups to exclude the effect of cancer
on circulating NET formation. Interestingly, circulating NET levels
showed signiﬁcant prognostic values in both cancer patients as
well as non-cancer patients (Fig 3). In addition, the association of cir-
culating NET levels with coagulation severity remained unchanged,
when analyzed in each cancer and non-cancer patient (data not
shown). Theseﬁndings suggest that the circulatingNET levels generated
in DIC processes provide prognostic signiﬁcance regardless of the
presence of cancer.
Specimen type is important when measuring circulating DNA
levels because in vitro clot formation in serum results in an increase
of artiﬁcially generated DNA increment in specimen tube [24].
Hence, using plasma instead of serum can assess more accurate
values reﬂecting in vivo circulating levels of DNA. Our study mea-
sured the circulating levels of DNA-histone complexes and dsDNA
in plasma, thus representing true in vivo condition.
The current study has a few limitations. First, althoughwemeasured
the circulating DNA-histone complexes and dsDNA but we could not
visualize the real NET formation due to methodological limitations.
Second, we could not explain the detailed changes associated with cir-
culating DNA-histone complexes and dsDNA because this was designed
to be a cross-sectional study representing one speciﬁc point in time.
Third, we did not evaluate the NET levels with respect to cancer stage.
The cancer patients in this study were of various types including
stomach, lung, pancreas, breast and prostate cancers, which made it
unfeasible to analyze the relationship for each cancer type. However,
the signiﬁcant correlation of NET levels with coagulation severity was
observed, suggesting it to be a good representative of DIC severity
regardless of cancer stage. Fourth, the assay kits for DNA-histone com-
plexes and dsDNA testing could not be used for clinical use so far. Future
studies are required to evaluate the test performance and to validate the
usefulness.Conclusions
We demonstrated that circulating DNA-histone complexes and
dsDNA correlated well with DIC severity. In addition, the high levels of
circulating DNA-histone complexes and dsDNA showed signiﬁcantly
independent prognostic values in DIC. These ﬁndings provide a new in-
sight into the potential clinical relevance of circulating DNA-histone
complex and dsDNA, which serve as powerful markers for mortality
prediction of DIC in future.Conﬂict of Interest Statement
The authors declare that they have no conﬂict of interest.
1069J.-E. Kim et al. / Thrombosis Research 135 (2015) 1064–1069Acknowledgement
This researchwas supported by a grant of the Korea Health Technol-
ogy R&D Project through the Korea Health Industry Development Insti-
tute (KHIDI), funded by the Ministry of Wealth &Welfare, Republic of
Korea (grant number: HI13C0954).
References
[1] Martinod K,Wagner DD. Thrombosis: tangled up in NETs. Blood 2014;123:2768–76.
[2] Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular
histones are major mediators of death in sepsis. Nat Med 2009;15:1318–21.
[3] Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers Jr DD, et al.
Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:
15880–5.
[4] Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second
function of chromatin? J Cell Biol 2012;198:773–83.
[5] Arai Y, Yamashita K, Mizugishi K, Watanabe T, Sakamoto S, Kitano T, et al. Serum
neutrophil extracellular trap levels predict thromboticmicroangiopathy after allogeneic
stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1683–9.
[6] Borissoff JI, Joosen IA, Versteylen MO, Brill A, Fuchs TA, Savchenko AS, et al. Elevated
levels of circulating DNA and chromatin are independently associated with severe
coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol
2013;33:2032–40.
[7] van Montfoort ML, Stephan F, Lauw MN, Hutten BA, Van Mierlo GJ, Solati S, et al.
Circulating nucleosomes and neutrophil activation as risk factors for deep vein
thrombosis. Arterioscler Thromb Vasc Biol 2013;33:147–51.
[8] ChenQ, Ye L, Jin Y, Zhang N, Lou T, Qiu Z, et al. Circulating nucleosomes as a predictor
of sepsis and organ dysfunction in critically ill patients. Int J Infect Dis 2012;16:
e558–64.
[9] Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment
of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc
Natl Acad Sci U S A 2010;107:9813–8.
[10] Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F, et al. Circulating histones are
mediators of trauma-associated lung injury. Am J Respir Crit Care Med 2013;187:
160–9.
[11] Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management
of disseminated intravascular coagulation. British Committee for Standards in
Haematology. Br J Haematol 2009;145:24–33.[12] Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientiﬁc Subcommittee on
Disseminated Intravascular Coagulation of the International Society on T, et al.
Towards deﬁnition, clinical and laboratory criteria, and a scoring system for dissem-
inated intravascular coagulation. Thromb Haemost 2001;86:1327–30.
[13] Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al.
Neutrophil extracellular traps kill bacteria. Science 2004;303:1532–5.
[14] Altincicek B, Stotzel S, Wygrecka M, Preissner KT, Vilcinskas A. Host-derived extra-
cellular nucleic acids enhance innate immune responses, induce coagulation, and
prolong survival upon infection in insects. J Immunol 2008;181:2705–12.
[15] Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. Extracellular histones increase
plasma thrombin generation by impairing thrombomodulin-dependent protein C
activation. J Thromb Haemost 2011;9:1795–803.
[16] Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombo-
cytopenia in mice. Blood 2011;118:3708–14.
[17] Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, et al.
Elevated nucleosome levels in systemic inﬂammation and sepsis. Crit Care Med
2003;31:1947–51.
[18] Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ
dysfunction. Thromb Res 2012;129:290–5.
[19] Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA concentration as
a predictor of mortality and sepsis in critically ill patients. Crit Care 2006;10:R60.
[20] Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, et al. Plasma con-
centrations and importance of High Mobility Group Box protein in the prognosis
of organ failure in patients with disseminated intravascular coagulation. Thromb
Haemost 2005;94:975–9.
[21] Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, et al. Circulating
nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in
patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer
2013;133:2619–30.
[22] Peitsch MC, Hesterkamp T, Polzar B, Mannherz HG, Tschopp J. Functional character-
isation of serum DNase I in MRL-lpr/lpr mice. Biochem Biophys Res Commun 1992;
186:739–45.
[23] Madoiwa S, Tanaka H, Nagahama Y, Dokai M, Kashiwakura Y, Ishiwata A, et al.
Degradation of cross-linked ﬁbrin by leukocyte elastase as alternative pathway
for plasmin-mediated ﬁbrinolysis in sepsis-induced disseminated intravascular
coagulation. Thromb Res 2011;127:349–55.
[24] Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma
and serum samples: higher concentrations of genomic DNA found in serum than in
plasma. Transfusion 2001;41:276–82.
